Premier Research acquires a CRO specializing in women’s health and diagnostics
MORRISVILLE, North Carolina, July 20, 2021 / PRNewswire / – World-class research announced today that it has acquired Health The decisions, a Durham, North Carolina– a contract research organization (CRO) focused on clinical development in all areas of women’s health and diagnostics. Premier Research is a leading provider of clinical research and development, as well as policy and regulatory advisory services to the biotechnology, specialty pharmacy and medical device industries.
“This is a pivotal moment for women’s health as unmet needs continue to grow. The women’s health market is expected to reach 40 billion dollars in the next five years and new technologies will multiply. Fortunately, big data provides new information on prevention and treatment for breast and pelvic health. But a major driver of market growth is the increasing incidence of diseases and disorders specific to women around the world, from osteoporosis and osteoarthritis to anemia and hormonal imbalances, ”said Krista armstrong, Ph.D., Senior Vice President, Clinical Development Services, Premier Research.
“The expertise in integrating Health Decisions into women’s health and diagnostic studies is a perfect complement to our CRO and advisory services for biotechnology and device sponsors, particularly in oncology, analgesia and in neuroscience. We can help customers capture this unprecedented moment in the women’s health market. with our broad and differentiated services – from expert regulatory strategy and global clinical trial management, to the transparency and ease of the PremierOne ecosystem that aggregates and coordinates administrative, financial and patient data, ”added Armstrong .
“The women’s health market has seen tremendous investment and expansion in all key aspects including Femtech over the past five years. In addition, the market opportunity for fluid-based diagnostics, especially in oncology, infectious disease, and women’s health, supports unprecedented levels. research in these areas. This collaboration gives sponsors the benefit of our in-depth understanding of women-centered trials and diagnostics, coupled with Premier Research’s strong global footprint and extensive service capabilities. Sponsors will now have access to the best holistic solutions in both of these areas, ”said Dr. Patrick phillips, CEO, Healthcare Decisions. “Together, we look forward to bringing great value to drug developers and others who seek to help improve health care outcomes for women around the world.”
Health Decisions is focused on research and diagnosis in women’s health and is supported by a network of 500 women’s health sites. Since 1989, the company has conducted more than 300 clinical trials, including more than 200 studies on female health indications such as reproductive and sexual health, menopause, pain management, osteoporosis, osteoarthritis and l gynecological oncology. He has also issued several PMAs and 510 (k) s for IVD-focused sponsors that include successful submissions for high-risk HPV, colorectal cancer, and premature birth, among others.
About Premier Research
Premier Research, a clinical research and development company, is dedicated to helping innovators in biotechnology, specialty pharmacy and devices transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier Research specializes in using innovative technologies for intelligent study design and trial management to deliver clear and conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing patient access, navigating global regulations, maximizing the impact of limited data on rare diseases or to provide expertise in specific therapeutic areas, Premier Research is committed to helping its clients meet the needs of patients across a wide range of medical conditions. Visit premier-research.com.
About health decisions
Health Decisions is a full-service contract research organization (CRO) providing therapeutic, operational and regulatory excellence for the clinical development of drugs, medical devices, and drug / device combinations in indications that have a profound and disproportionate impact on the women. Drawing on years of experience and aided by a site network of over 500 high performing women’s health sites, Health Decisions offers tailored clinical studies to meet the needs of sponsors, patients and regulations. Over 90% of Health Decisions staff specialize in women’s health research, enabling hand-selected study teams to address asset development challenges in areas such as reproductive health and sexual, menopause, pain management, osteoporosis, osteoarthritis and gynecologic oncology. In addition, Health Decisions conducts diagnostic and medical device studies in all therapeutic indications, including women’s health, oncology and infectious diseases. For more information visit www.healthdec.com.
Media contact: Karen brown, Vice-president, Marketing, [email protected]ier-research.com
SOURCE First Search